James Wilson, Consultant Clinical Oncologist at University College London Hospital, shared a post on LinkedIn:
“Metastatic melanoma. Two treatments. One transformation…
This is a PET scan of an elderly, frail patient with widespread metastatic melanoma. He presented with a high-risk spinal lesion, that I treated first with stereotactic radiotherapy (SABR/SBRT). We then started single-agent immunotherapy, which led to the right-hand image – after just two cycles. His performance status and functional capacity have improved dramatically.
A persistent left lung nodule was later treated with SABR, with an excellent response. Now he’s independent, active, and doing brilliantly. As a registrar, I wouldn’t have believed this outcome possible in metastatic melanoma. This case highlights the potential of targeted radiotherapy and modern immunotherapy – transforming outcomes, including quality of life, even in advanced disease.
What treatments are you offering now that felt impossible earlier in your career?”
